Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study

What Was Tested

This clinical trial paper looks at Liraglutide in the context of fatty liver & elevated liver enzymes.

To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).

Who Took Part

According to the abstract, 29 subjects were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years).

How the Study Was Run

The design is described as pilot.

It is described as a pilot, a small early test of whether a larger Liraglutide study would be practical.

What Was Measured

The subject headings attached to it are Atherosclerosis, Carotid Intima-Media Thickness, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Lipids and Liraglutide.

Author keywords: non-alcoholic fatty liver disease and type 2 diabetes.

What This Means in Plain Language

The paper is a pilot study of Liraglutide in 29 subjects in people with fatty liver & elevated liver enzymes.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Expert opinion on biological therapy), a journal based in England.

More context: the Liraglutide compound page, Fatty liver & elevated liver enzymes research.